First Horizon Advisors’s Beam Therapeutics BEAM Stock Holding History

First Horizon Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$11.7K	Sell	685 -338	-33%	-$5.89K	﹤0.01%	1619
2025 Q1	$20K	Sell	1,023 -14	-1%	-$367	﹤0.01%	1323
2024 Q4	$25.7K	Buy	1,037 +52	+5%	+$1.33K	﹤0.01%	1231
2024 Q3	$24.1K	Sell	985 -17	-2%	-$439	﹤0.01%	1287
2024 Q2	$23.5K	Hold	1,002	–	–	﹤0.01%	1218
2024 Q1	$33.1K	Buy	1,002 +8	+0.8%	+$249	﹤0.01%	1146
2023 Q4	$27.1K	Buy	994 +554	+126%	+$13.8K	﹤0.01%	1213
2023 Q3	$10.6K	Sell	440 -187	-30%	-$5.01K	﹤0.01%	1488
2023 Q2	$20K	Sell	627 -54	-8%	-$1.75K	﹤0.01%	1271
2023 Q1	$20.9K	Sell	681 -2	-0.3%	-$79	﹤0.01%	1252
2022 Q4	$26.7K	Buy	+683	New	+$30.6K	﹤0.01%	1147

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Horizon Advisors's BEAM Position: Q2 2025 in Review

First Horizon Advisors reduced its Beam Therapeutics (BEAM) stake by 33% in Q2 2025, selling an estimated $5.89K and leaving 685 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1619.

First Horizon Advisors first reported a position in BEAM in Q4 2022 and has held it in 11 quarters since. The position peaked at $33.1K in Q1 2024. 216 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

First Horizon Advisors held 685 shares of Beam Therapeutics worth $11.7K as of Q2 2025.
First Horizon Advisors sold 338 Beam Therapeutics shares in Q2 2025, an estimated $5.89K.
Beam Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1619 holding.
First Horizon Advisors first reported a position in Beam Therapeutics in Q4 2022 and has held it in 11 quarters since.
First Horizon Advisors's Beam Therapeutics position peaked at $33.1K in Q1 2024.
216 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.